CoChat

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectively controls the growth of distinct (transplantable, carcinogen- or oncogene induced) orthotopic NSCLC models. These anticancer effects are linked to increased T lymphocyte infiltration and are abolished by T cell depletion or interferon-γ neutralization. Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Hence, a sequential combination treatment consisting in conventional chemotherapy together with crizotinib, followed by immune checkpoint blockade may be active against NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09415-3

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of (R)-crizotinib as a novel immunogenic cell death inducer. a Human osteosarcoma U2OS cells stably co-expressing calreticulin (CALR)-RFP and HMGB1-GFP or GFP-LC3 were treated with the compounds from the Public Chemogenomic Set for Protein Kinases at a concentration of 10 µM for 8 h, 12 h and 32 h, followed by the assessment of CALR exposure (CALR-RFP redistribution), autophagy (GFP-LC3 granularity) and HMGB1 release (decrease of nuclear HMGB1-GFP intensity), respectively. Nuclear pyknosis was monitored as an indicator for cell death. The data was normalized to calculate Z scoring (mean, n = 4, Supplementary data 1) and the effects of the agents are hierarchically clustered in a heatmap. Top hits are separately displayed with red and blue reporting positive and negative values, respectively. b A collection of tyrosine kinase inhibitors (final concentrations 5, 10 µM) was screened following the same approach. Z score was calculated for each agent (mean, n = 4, Supplementary data 2). c Representative images of (R)-crizotinib (Criz) induced ICD phenotypes are depicted and the scale bar equals 10 µm. d ICD inducing effects of (R)/(S)-crizotinib in combination with cisplatin (CDDP; 150 µM) and mitomycin C (MitoC; 150 µM). Human osteosarcoma U2OS cells, murine fibrosarcoma MCA205 cells, as well as murine NSCLC TC1 cells were treated with mitoxantrone (MTX; 2 µM), CDDP, MitoC alone or in combination with increasing concentrations (1, 5, 10 µM) of (R) or (S)-crizotinib, for 24 h before determination CALR exposure (by flow cytometry), ATP secretion (ATP-dependent luminescence kit), and HMGB1 release (ELISA). Results are normalized as log2 and shown as a heatmap in which each rectangle represents the mean of triplicate assessment, statistical significances are indicated as *p < 0.001 comparing to controls using Student’s t-test
Fig. 1 Identification of (R)-crizotinib as a novel immunogenic cell death inducer. a Human osteosarcoma U2OS cells stably co-expressing calreticulin (CALR)-RFP and HMGB1-GFP or GFP-LC3 were treated with the compounds from the Public Chemogenomic Set for Protein Kinases at a concentration of 10 µM for 8 h, 12 h and 32 h, followed by the assessment of CALR exposure (CALR-RFP redistribution), autophagy (GFP-LC3 granularity) and HMGB1 release (decrease of nuclear HMGB1-GFP intensity), respectively. Nuclear pyknosis was monitored as an indicator for cell death. The data was normalized to calculate Z scoring (mean, n = 4, Supplementary data 1) and the effects of the agents are hierarchically clustered in a heatmap. Top hits are separately displayed with red and blue reporting positive and negative values, respectively. b A collection of tyrosine kinase inhibitors (final concentrations 5, 10 µM) was screened following the same approach. Z score was calculated for each agent (mean, n = 4, Supplementary data 2). c Representative images of (R)-crizotinib (Criz) induced ICD phenotypes are depicted and the scale bar equals 10 µm. d ICD inducing effects of (R)/(S)-crizotinib in combination with cisplatin (CDDP; 150 µM) and mitomycin C (MitoC; 150 µM). Human osteosarcoma U2OS cells, murine fibrosarcoma MCA205 cells, as well as murine NSCLC TC1 cells were treated with mitoxantrone (MTX; 2 µM), CDDP, MitoC alone or in combination with increasing concentrations (1, 5, 10 µM) of (R) or (S)-crizotinib, for 24 h before determination CALR exposure (by flow cytometry), ATP secretion (ATP-dependent luminescence kit), and HMGB1 release (ELISA). Results are normalized as log2 and shown as a heatmap in which each rectangle represents the mean of triplicate assessment, statistical significances are indicated as *p < 0.001 comparing to controls using Student’s t-testCC BY · PubMed Central
Fig. 2 Mode of action of (R)-crizotinib induced ICD. a–h Investigation of crizotinib induced ICD in the NSCLC cell lines, NCI-H2228 and NCI-H1650, which are positive and negative for the EML4-ALK fusion protein, respectively. H1650 (EML4-ALK−) and H2228 (EML4-ALK+) cells were treated with mitoxantrone (MTX; 2 µM), or increasing concentrations (0.1, 0.5, 1, 2.5, 5, 10 µM) of (R)-crizotinib or (S)-crizotinib (Criz) for 72 h to assess cell death using AnnexinV, DAPI staining (a, b), and 24 h to determine immunogenic cell death parameters (c–h). i–l SiRNAs knockdown of crizotinib targeting kinases induces ICD similar to crizotinib. Indicated siRNAs (a pool of four siRNA duplexes or 4 individual sequences) were reversely transfected into U2OS cells or their derivatives stably co-expressing calreticulin (CALR)-RFP and HMGB1-GFP or GFP-LC3. Forty-eight h later the phosphorylation of eIF2α and other ICD hallmarks (CALR-RFP redistribution, GFP-LC3 granularity and HMGB1-GFP intensity) were assessed. Treatment of unrelated-siRNA-transfected cells with (R)-crizotinib for 24 h was used as a positive control. The capacity of siRNA-mediated knockdowns to induce ICD parameters was normalized to unrelated-siRNA-transfected cells. Data are shown as mean ± s.e.m. (n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, compared to unrelated siRNA using Student’s t-test)
Fig. 2 Mode of action of (R)-crizotinib induced ICD. a–h Investigation of crizotinib induced ICD in the NSCLC cell lines, NCI-H2228 and NCI-H1650, which are positive and negative for the EML4-ALK fusion protein, respectively. H1650 (EML4-ALK−) and H2228 (EML4-ALK+) cells were treated with mitoxantrone (MTX; 2 µM), or increasing concentrations (0.1, 0.5, 1, 2.5, 5, 10 µM) of (R)-crizotinib or (S)-crizotinib (Criz) for 72 h to assess cell death using AnnexinV, DAPI staining (a, b), and 24 h to determine immunogenic cell death parameters (c–h). i–l SiRNAs knockdown of crizotinib targeting kinases induces ICD similar to crizotinib. Indicated siRNAs (a pool of four siRNA duplexes or 4 individual sequences) were reversely transfected into U2OS cells or their derivatives stably co-expressing calreticulin (CALR)-RFP and HMGB1-GFP or GFP-LC3. Forty-eight h later the phosphorylation of eIF2α and other ICD hallmarks (CALR-RFP redistribution, GFP-LC3 granularity and HMGB1-GFP intensity) were assessed. Treatment of unrelated-siRNA-transfected cells with (R)-crizotinib for 24 h was used as a positive control. The capacity of siRNA-mediated knockdowns to induce ICD parameters was normalized to unrelated-siRNA-transfected cells. Data are shown as mean ± s.e.m. (n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, compared to unrelated siRNA using Student’s t-test)CC BY · PubMed Central
Fig. 3 (R)-crizotinib had anti-cancer vaccination effects on NSCLC. Wild type (WT) TC1 cells were treated with mitoxantrone (MTX; 4 µM), cisplatin (CDDP; 150 µM), mitomycin C (MitoC; 150 µM) alone or in combination with (R)-crizotinib (Criz, 10 µM) for 24 h. Then the cells were collected and subcutaneously (s.c.) injected (106 cells per mouse) into the left flank of immunocompetent C57BL/6 mice (a). PBS was used as control. Two weeks later all mice were rechallenged with living TC1 cells (2 × 105 per mouse) in the right flank. The evolution of tumor incidence over time was reported as Kaplan–Meier curves (b–d). Statistical significance was calculated by means of the Likelihood ratio test. ***p < 0.001 compared to PBS group; n = 10 per group. Final tumor size distribution at endpoint is shown in e. Statistical significance was calculated by means of the ANOVA test for multiple comparisons, ***p < 0.001 as compared to the PBS group. f, g ANXA1-deficient (Anxa1−/−) or HMGB1-deficient (Hmgb1−/−) TC1 cells treated 24 h with (R)-crizotinib/CDDP combination or receiving an equivalent volume of PBS were s.c. inoculated in the flank of WT C57BL/6 mice, which were 2 weeks later rechallenged in the opposite flank with living TC1 cells. h, i WT TC1 cells treated 24 h with the combination of (R)-Criz and CDDP were incubated with chicken αCALR antibody or isotype antibody (2.5 µg per 106 cells) for 30 min at room temperature; or an ATP diphosphohydrolase apyrase (5 IU per 106 cells) for 30 min at room temperature before being inoculated s.c. into the flank of WT C57BL/6 mice, which were 2 weeks later rechallenged in the opposite flank later with living TC1 cells. Statistical significance was calculated by means of the Likelihood ratio test. ***p < 0.001 compared to PBS group; ###p < 0.001 as comparing indicated groups, n = minimum of 6 mice per group
Fig. 3 (R)-crizotinib had anti-cancer vaccination effects on NSCLC. Wild type (WT) TC1 cells were treated with mitoxantrone (MTX; 4 µM), cisplatin (CDDP; 150 µM), mitomycin C (MitoC; 150 µM) alone or in combination with (R)-crizotinib (Criz, 10 µM) for 24 h. Then the cells were collected and subcutaneously (s.c.) injected (106 cells per mouse) into the left flank of immunocompetent C57BL/6 mice (a). PBS was used as control. Two weeks later all mice were rechallenged with living TC1 cells (2 × 105 per mouse) in the right flank. The evolution of tumor incidence over time was reported as Kaplan–Meier curves (b–d). Statistical significance was calculated by means of the Likelihood ratio test. ***p < 0.001 compared to PBS group; n = 10 per group. Final tumor size distribution at endpoint is shown in e. Statistical significance was calculated by means of the ANOVA test for multiple comparisons, ***p < 0.001 as compared to the PBS group. f, g ANXA1-deficient (Anxa1−/−) or HMGB1-deficient (Hmgb1−/−) TC1 cells treated 24 h with (R)-crizotinib/CDDP combination or receiving an equivalent volume of PBS were s.c. inoculated in the flank of WT C57BL/6 mice, which were 2 weeks later rechallenged in the opposite flank with living TC1 cells. h, i WT TC1 cells treated 24 h with the combination of (R)-Criz and CDDP were incubated with chicken αCALR antibody or isotype antibody (2.5 µg per 106 cells) for 30 min at room temperature; or an ATP diphosphohydrolase apyrase (5 IU per 106 cells) for 30 min at room temperature before being inoculated s.c. into the flank of WT C57BL/6 mice, which were 2 weeks later rechallenged in the opposite flank later with living TC1 cells. Statistical significance was calculated by means of the Likelihood ratio test. ***p < 0.001 compared to PBS group; ###p < 0.001 as comparing indicated groups, n = minimum of 6 mice per groupCC BY · PubMed Central
Fig. 4 (R)-crizotinib in combination with CDDP or MitoC had synergistic anti-cancer effects on established orthotopic NSCLC model. Living TC1 cells stably expressing luciferase activity (TC1 Luc, 5 × 105 per mouse) were intravenously (i.v.) injected into wild type C57BL/6 mice (n = 10 mice per group) (b-h) or nude mice (nu/nu; n = 7 per group) (l–n) until tumor incidence in the lung can be detected by bioluminescence. Then mice received repeated treatments with solvent control (Sol), mitoxantrone (MTX; i.p., 5.2 mg Kg−1), cisplatin (CDDP; i.p., 0.25 mg Kg−1), mitomycin C (MitoC; i.p., 0.25 mg Kg−1) alone or in combination with (R)-crizotinib or (S)-crizotinib (Criz, i.p., 50 mg Kg−1) at day 0 and day 2. Tumor size was monitored by luciferase activity every 4 days (a). Representative time lapse images of a control mouse and a cured animal are reported in b; average (mean ± s.e.m.) tumor growth curves are reported in c, f, l; percentage of tumor free mice are reported in d, g, m; overall survival are reported in e, h, n. i–k cured immunocompetent mice were rechallenged with living cancer cells of the same type (TC1), as well as different type (MCA205), tumor size was monitored accordingly (j). A group of naïve mice were used to confirm the normal growth of both cell types (k). Statistical significance was calculated by means of the ANOVA Type 2 (Wald test) for tumor growth curves, or Likelihood ratio test for tumor-free and overall survival curves. ns, not significant; *p < 0.05, ***p < 0.001 compared to Sol
Fig. 4 (R)-crizotinib in combination with CDDP or MitoC had synergistic anti-cancer effects on established orthotopic NSCLC model. Living TC1 cells stably expressing luciferase activity (TC1 Luc, 5 × 105 per mouse) were intravenously (i.v.) injected into wild type C57BL/6 mice (n = 10 mice per group) (b-h) or nude mice (nu/nu; n = 7 per group) (l–n) until tumor incidence in the lung can be detected by bioluminescence. Then mice received repeated treatments with solvent control (Sol), mitoxantrone (MTX; i.p., 5.2 mg Kg−1), cisplatin (CDDP; i.p., 0.25 mg Kg−1), mitomycin C (MitoC; i.p., 0.25 mg Kg−1) alone or in combination with (R)-crizotinib or (S)-crizotinib (Criz, i.p., 50 mg Kg−1) at day 0 and day 2. Tumor size was monitored by luciferase activity every 4 days (a). Representative time lapse images of a control mouse and a cured animal are reported in b; average (mean ± s.e.m.) tumor growth curves are reported in c, f, l; percentage of tumor free mice are reported in d, g, m; overall survival are reported in e, h, n. i–k cured immunocompetent mice were rechallenged with living cancer cells of the same type (TC1), as well as different type (MCA205), tumor size was monitored accordingly (j). A group of naïve mice were used to confirm the normal growth of both cell types (k). Statistical significance was calculated by means of the ANOVA Type 2 (Wald test) for tumor growth curves, or Likelihood ratio test for tumor-free and overall survival curves. ns, not significant; *p < 0.05, ***p < 0.001 compared to SolCC BY · PubMed Central
Fig. 5 (R)-crizotinib in combination with CDDP had synergistic antitumor effect on oncogene and carcinogen-induced lung cancer models. a–d KrasLSL−G12D/+; Trp53flox/flox (KP) mice were used as a conditional mouse model of NSCLC, tumor initiation and drug treatments were performed according to the scheme demonstrated in a. At the end of the experiment, all mice were euthanized and lungs were sampled to measure weight and subjected to further hematoxylin-eosin staining and immunohistochemistry. Representative hematoxylin-eosin stained lung lobes of KP mice that were treated with either solvent (Sol) or the combination of (R)-crizotinib (Criz) with cisplatin (CDDP) are shown in b. Lung weight was used as proxy of tumor burden and is depicted for tumor-free (Ctrl) and treated tumor-bearing mice (c). Hematoxylin-eosin based tumor area quantification on lung lobe sections of KP mice is presented (d). Results are expressed as mean ± s.e.m. *p < 0.05; ***p < 0.001 as compared to Sol, #p < 0.05 as comparing indicated groups using Student’s t-test, n = minimum of 6 mice per group. Friend Virus B (FVB) mice were used as a spontaneous mouse model of lung adenocarcinoma, tumor induction and drug treatments were performed according to the scheme demonstrated in e. Tumor development was monitored with microCT photographing and all mice were euthanized to obtain lung lobes for further histology. Representative stereo microscope scans of lung lobes (f), as well as quantified neoplasia numbers (g, h) and tumor sizes (i) are reported. Results are expressed as mean ± s.e.m. **p < 0.01; ***p < 0.001 as compared to Sol, ##p < 0.01 as comparing neoplasia numbers in specific size using Student’s t-test, scale bar equals 1 mm, n = minimum of 9 mice per group
Fig. 5 (R)-crizotinib in combination with CDDP had synergistic antitumor effect on oncogene and carcinogen-induced lung cancer models. a–d KrasLSL−G12D/+; Trp53flox/flox (KP) mice were used as a conditional mouse model of NSCLC, tumor initiation and drug treatments were performed according to the scheme demonstrated in a. At the end of the experiment, all mice were euthanized and lungs were sampled to measure weight and subjected to further hematoxylin-eosin staining and immunohistochemistry. Representative hematoxylin-eosin stained lung lobes of KP mice that were treated with either solvent (Sol) or the combination of (R)-crizotinib (Criz) with cisplatin (CDDP) are shown in b. Lung weight was used as proxy of tumor burden and is depicted for tumor-free (Ctrl) and treated tumor-bearing mice (c). Hematoxylin-eosin based tumor area quantification on lung lobe sections of KP mice is presented (d). Results are expressed as mean ± s.e.m. *p < 0.05; ***p < 0.001 as compared to Sol, #p < 0.05 as comparing indicated groups using Student’s t-test, n = minimum of 6 mice per group. Friend Virus B (FVB) mice were used as a spontaneous mouse model of lung adenocarcinoma, tumor induction and drug treatments were performed according to the scheme demonstrated in e. Tumor development was monitored with microCT photographing and all mice were euthanized to obtain lung lobes for further histology. Representative stereo microscope scans of lung lobes (f), as well as quantified neoplasia numbers (g, h) and tumor sizes (i) are reported. Results are expressed as mean ± s.e.m. **p < 0.01; ***p < 0.001 as compared to Sol, ##p < 0.01 as comparing neoplasia numbers in specific size using Student’s t-test, scale bar equals 1 mm, n = minimum of 9 mice per groupCC BY · PubMed Central
Fig. 6 (R)-crizotinib induces immune infiltration in established tumors. MCA205 tumors-bearing mice received injections (i.p.) of solvent (Sol), cisplatin (CDDP), (R)-crizotinib (Criz) or the combination at day 0 (when tumors became palpable) and day 2. Samples were harvested at day 8 for immunofluorescence staining (a); or RNA extraction for qPCR analysis using primers for CTLA-4, PD-1 and PD-L1 (l), n = 12 per group. Alternatively tumors were harvested at day 10 for flow cytometry (n = 7 per group) (b–d, m–o), or RNA extraction and RNASeq analysis (n = 4 per group) (e, f). a CD8+/Foxp3+ ratios are depicted as mean ± s.e.m. ***p < 0.001 as compared to Sol, ##p < 0.01 as comparing indicated groups using Student’s t-test. (b-d) IFNγ-producing and IL-17-producing T cells were quantified by flow cytometry and are reported as dot plots. Statistical significance was calculated using two-way ANOVA test, *p < 0.05; **p < 0.01; as compared to Sol. e, f GO term enrichment analysis for T cell activation related genes are depicted as fold change (FC) with adjusted P values (P) for the condition Sol vs. (R)-Criz + CDDP (f). WT C57BL/6 mice bearing subcutaneous (s.c.) MC205 (g), s.c. TC1 (h), or orthotopic TC1 Luc tumors (i–k) were treated with Sol or (R)-Criz + CDDP, accompanied by systemic administration of an IFNγ neutralizing antibody (αIFNγ) or or isotype antibody (αIso). Statistical significance was calculated by ANOVA Type 2 (Wald test) for tumor growth, or Likelihood ratio test for tumor incidence and overall survival. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001 compared to Sol. l qPCR analysis of CTLA-4, PD-1 and PD-L1 mRNA in MCA205 tumors. Expressions of immune checkpoint markers on tumor infiltrating CD4+FOXP3−ICOS+ (m) or CD4+FOXP3+ICOS+ (n) T cells were quantified by flow cytometry. The frequency of CTLA-4+PD-1−, CTLA-4−PD-1+ or CTLA-4+PD-1+ cells was determined among the indicated subsets. Statistical significance was calculated by two-way ANOVA test for multiple comparisons, *p < 0.05; **p < 0.01; ***p < 0.001 as compared to Sol; ##p < 0.01; ###p < 0.001 as compared to CDDP; †p < 0.01; ††p < 0.001 as compared to (R)-Criz
Fig. 6 (R)-crizotinib induces immune infiltration in established tumors. MCA205 tumors-bearing mice received injections (i.p.) of solvent (Sol), cisplatin (CDDP), (R)-crizotinib (Criz) or the combination at day 0 (when tumors became palpable) and day 2. Samples were harvested at day 8 for immunofluorescence staining (a); or RNA extraction for qPCR analysis using primers for CTLA-4, PD-1 and PD-L1 (l), n = 12 per group. Alternatively tumors were harvested at day 10 for flow cytometry (n = 7 per group) (b–d, m–o), or RNA extraction and RNASeq analysis (n = 4 per group) (e, f). a CD8+/Foxp3+ ratios are depicted as mean ± s.e.m. ***p < 0.001 as compared to Sol, ##p < 0.01 as comparing indicated groups using Student’s t-test. (b-d) IFNγ-producing and IL-17-producing T cells were quantified by flow cytometry and are reported as dot plots. Statistical significance was calculated using two-way ANOVA test, *p < 0.05; **p < 0.01; as compared to Sol. e, f GO term enrichment analysis for T cell activation related genes are depicted as fold change (FC) with adjusted P values (P) for the condition Sol vs. (R)-Criz + CDDP (f). WT C57BL/6 mice bearing subcutaneous (s.c.) MC205 (g), s.c. TC1 (h), or orthotopic TC1 Luc tumors (i–k) were treated with Sol or (R)-Criz + CDDP, accompanied by systemic administration of an IFNγ neutralizing antibody (αIFNγ) or or isotype antibody (αIso). Statistical significance was calculated by ANOVA Type 2 (Wald test) for tumor growth, or Likelihood ratio test for tumor incidence and overall survival. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001 compared to Sol. l qPCR analysis of CTLA-4, PD-1 and PD-L1 mRNA in MCA205 tumors. Expressions of immune checkpoint markers on tumor infiltrating CD4+FOXP3−ICOS+ (m) or CD4+FOXP3+ICOS+ (n) T cells were quantified by flow cytometry. The frequency of CTLA-4+PD-1−, CTLA-4−PD-1+ or CTLA-4+PD-1+ cells was determined among the indicated subsets. Statistical significance was calculated by two-way ANOVA test for multiple comparisons, *p < 0.05; **p < 0.01; ***p < 0.001 as compared to Sol; ##p < 0.01; ###p < 0.001 as compared to CDDP; †p < 0.01; ††p < 0.001 as compared to (R)-CrizCC BY · PubMed Central
Fig. 7 Immunogenic chemotherapy of (R)-crizotinib sensitizes NSCLC tumors to checkpoint blockades. a–c Treatment of subcutaneous (s.c.) TC1 tumors with injections of solvent control, CDDP alone or in combination with (R)-crizotinib. Isotype monocloncal antibodies (mAbs) or anti-PD-1 mAbs (αpd-1) combined with anti-CTLA-4 mAbs (αCTLA-4) were injected on day 8, 12, and 16 (schedule in a). Tumor growth was monitored (b, c) and expressed as surface (mean ± s.e.m., b) or size at endpoint (box plot, c). d–j Treatment of orthotopic TC1 Luc tumors. Once the presence of lung cancer could be detected by bioluminescence (day 0), the animals were treated according to the scheme (d). Representative images of tumor development are shown in e; average (mean ± s.e.m.) bioluminescence signals are reported in f; final values at endpoint are reported as box plot in g. The percentage of tumor free mice is reported in h; overall survival is reported in i. Data in e–i include dual checkpoint blockade (αCTLA-4/αPD-1). The effects of dual as compared to single checkpoint blockade at day 70 are shown in j. Statistical significance was calculated by means of the ANOVA Type 2 (Wald test) (b, f), ANOVA test for multiple comparisons (c, g), Likelihood ratio test (h, i) or χ2 test (j). *p < 0.05, **p < 0.01, ***p < 0.001 as compared to control group with isotype; #p < 0.05, ##p < 0.01, ###p < 0.001 as compared to control group with the combination of αPD-1 and αCTLA-4; †††p < 0.001 comparing isotype and αCTLA-4 and αPD-1 combination, n = minimum of 10 animals per group
Fig. 7 Immunogenic chemotherapy of (R)-crizotinib sensitizes NSCLC tumors to checkpoint blockades. a–c Treatment of subcutaneous (s.c.) TC1 tumors with injections of solvent control, CDDP alone or in combination with (R)-crizotinib. Isotype monocloncal antibodies (mAbs) or anti-PD-1 mAbs (αpd-1) combined with anti-CTLA-4 mAbs (αCTLA-4) were injected on day 8, 12, and 16 (schedule in a). Tumor growth was monitored (b, c) and expressed as surface (mean ± s.e.m., b) or size at endpoint (box plot, c). d–j Treatment of orthotopic TC1 Luc tumors. Once the presence of lung cancer could be detected by bioluminescence (day 0), the animals were treated according to the scheme (d). Representative images of tumor development are shown in e; average (mean ± s.e.m.) bioluminescence signals are reported in f; final values at endpoint are reported as box plot in g. The percentage of tumor free mice is reported in h; overall survival is reported in i. Data in e–i include dual checkpoint blockade (αCTLA-4/αPD-1). The effects of dual as compared to single checkpoint blockade at day 70 are shown in j. Statistical significance was calculated by means of the ANOVA Type 2 (Wald test) (b, f), ANOVA test for multiple comparisons (c, g), Likelihood ratio test (h, i) or χ2 test (j). *p < 0.05, **p < 0.01, ***p < 0.001 as compared to control group with isotype; #p < 0.05, ##p < 0.01, ###p < 0.001 as compared to control group with the combination of αPD-1 and αCTLA-4; †††p < 0.001 comparing isotype and αCTLA-4 and αPD-1 combination, n = minimum of 10 animals per groupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 303

Metadata

Authors
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., Senovilla, L., Bezu, L., Vacchelli, E., Sica, V., Melis, A., Martin, T., Xia, L., Yang, H., Li, Q., Chen, J., Durand, S., Aprahamian, F., Lefevre, D., Broutin, S., Paci, A., Bongers, A., Minard-Colin, V., Tartour, E., Zitvogel, L., Apetoh, L., Ma, Y., Pittet, M. J., Kepp, O., & Kroemer, G.
Affiliations
  • Université Paris-Sud (FR)
  • Inserm (FR)
  • Harvard University (US)
  • Massachusetts Institute of Technology (US)
  • Weill Cornell Medicine (US)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Institut Gustave Roussy (FR)
  • Karolinska University Hospital (SE)
Corresponding author
  • Kepp, Oliver
  • Kroemer, Guido
Venue
Nature Communications
Published
2019-04-02
Volume
10
Issue
1
Pages
1486-1486
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2930737113
Cited by
302
References
52
Citations by year
2026: 23 · 2025: 33 · 2024: 40 · 2023: 53 · 2022: 49 · 2021: 50 · 2020: 37 · 2019: 17
FWCI
16.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • theses.fr (ABES) (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
  • Association pour la Recherche sur le Cancer
  • Seerave Foundation
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • E-Rare
  • European Commission (HORIZON2020)
  • Agence Nationale de la Recherche (E-Rare-2)
  • Fondation Leducq
  • Institut National de la Santé et de la Recherche Médicale
  • National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
  • Fondation pour la Recherche Médicale (677251)
  • Government of Jiangsu Province
  • Ligue Contre le Cancer
  • China Scholarship Council
  • Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
  • Institut Universitaire de France
  • Institut National Du Cancer
  • Recruitment Program of Global Experts
  • National Institutes of Health (2016-I2M-1-005, CA163109)
  • Ludwig Center at Harvard
  • National Key Research and Development Program of China (2017YFA0506200)
  • Labex Immuno-Oncology
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine ((CAMS-I2M), 2016-I2M-1-005, CAMS-I2M, 2016-I2M-1-005)
  • National Cancer Institute (U54CA163109)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
crizotinib, immunogenic cell death, non-small cell lung cancer, cisplatin, tyrosine kinase inhibitors, combination chemotherapy, T cell infiltration, PD-1, PD-L1, immune checkpoint blockade, antitumor immunity, interferon-gamma
MeSH terms
Crizotinib, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Interferon-gamma, Lung Neoplasms, Mice, Inbred C57BL, T-Lymphocytes, Cell Death, Cell Line, Tumor, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Crizotinib-induced immunogenic cell death in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-019-09415-3
The paper
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., Senovilla, L., Bezu, L., Vacchelli, E., Sica, V., Melis, A., Martin, T., Xia, L., Yang, H., Li, Q., . . . Kroemer, G. (2019). Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-019-09415-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.